Increased circulating butyrate and ursodeoxycholate during probiotic intervention in humans with type 2 diabetes.

ABSTRACT:

Background

An increasing body of evidence implicates the resident gut microbiota as playing a critical role in type 2 diabetes (T2D) pathogenesis. We previously reported significant improvement in postprandial glucose control in human participants with T2D following 12-week administration of a 5-strain novel probiotic formulation ('WBF-011') in a double-blind, randomized, placebo controlled setting (NCT03893422). While the clinical endpoints were encouraging, additional exploratory measurements were needed in order to link the motivating mechanistic hypothesis - increased short-chain fatty acids - with markers of disease.

Results

Here we report targeted and untargeted metabolomic measurements on fasting plasma (n = 104) collected at baseline and end of intervention. Butyrate

SUBMITTER: McMurdie PJ 

PROVIDER: S-EPMC8742391 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature